The safety and strong antitumor effects of GPC1-specific CAR-T cells against GPC1-expressing solid tumors were demonstrated by using both syngeneic and xenogeneic mouse models.

The stanniocalcin-1-dependent immunosuppressive roles of mesenchymal stem cell on chimeric antigen receptor modified T cell therapy.

A family of engineered immune receptors trigger internalization of cancer cells and antigen-coated targets.

Oxygen levels at the time of T cell activation are major determinants of function, even when T cells are subsequently expanded in high levels of oxygen.

Designer transmembrane peptides precisely control chimeric antigen receptor signaling strength and are insulated from undesired interactions with endogenous receptors.

Rapid, label-free, volumetric, and automated assessment of the immunological synapse dynamics is demonstrated by combining optical diffraction tomography and deep-learning-based segmentation, providing a new option for immunological research.

Two cellular populations can be tracked in the same small animal model using near-infrared bioluminescence imaging, for the first time opening up the window for multi-coloured bioluminescence.

Binding of the translation initiation factor eIF3 to the messenger RNAs encoding the T cell receptor subunits alpha and beta is required to drive a short burst in their translation and promote a strong T cell response.

Human NK cells engineered to express a PD-L1 chimeric antigen receptor can control murine and human tumors and reduce myeloid cells expressing high levels of PD-L1.

Genetically engineered, CD73-redirected human NK cells show potent antitumor activity in vivo by impairing adenosinergic activity of CD73 in cancer.